GV, Alphabet Inc's venture capital arm, led a US$58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The company said it will only develop treatments that involve editing adult cells, so the effects of genetic manipulation cannot be passed on to future generations.
این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب:
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
Brazil cosmetics company Natura to invest US$5m in new brands through venture capital funds[SAO PAULO] Brazil cosmetics company Natura intends to invest up to US$5 million in new brands in beauty and wellness segments in Europe and the United States through venture capital funds, executives said on Friday. Read more at The Business Times.
منبع: BusinessTimes - 🏆 15. / 51 ادامه مطلب »
More funds to help companies train workers, raise wages
منبع: TODAYonline - 🏆 1. / 99 ادامه مطلب »
More funding for companies that work with unions to prepare workers for transformation: DPM HengSINGAPORE - Technological advancements should help workers do their jobs better, not replace them, said Deputy Prime Minister Heng Swee Keat on Wednesday (May 1).. Read more at straitstimes.com.
منبع: The Straits Times - 🏆 8. / 63 ادامه مطلب »